Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
A million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. Novo's pill had sales of 2.3 billion Danish ...
Mike Doustdar, Novo Nordisk CEO (Nichlas Pollier/Bloomberg via Getty Images) May 6, 2026 06:27 AM EDT Pharma Novo Nordisk's first quarter in four words: Pills, pricing, payments and pressure Elizabeth Cairns Senior biopharma journalist A million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that